Enanta Pharmaceuticals, Inc.
NASDAQ:ENTABiotechnology
-$0.09 today
- Market cap
- $239.70M
- Beta
- 0.99
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$2.90
Volume 0.81M
Average 0.17M
ENTA Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Enanta Pharmaceuticals, Inc.NASDAQ: ENTA
Other Income / Expenses · Q2 FY2026 · quarter ended Mar 2026
Other income / expenses turns negative
Q2 FY2026 other income / expenses was -$1.23M, compared with $578K a year earlier. Trailing-twelve-month other income / expenses was -$1.51M. Over 3 fiscal years it compounded at +2.8% a year.
Context
- Other income / expenses amounted to 2.8% of revenue in FY2025, down 3.0 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly other income / expenses holds near -$1.23M or moves back toward the trailing-twelve-month quarterly average of -$377K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 1.8M USD
- Year-over-year change
- -53.9%
- 4-year CAGR
- -2.5%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 1.8M | -53.9% |
| FY2024 | 2024-09-30 | 3.9M | -37.2% |
| FY2023 | 2023-09-30 | 6.21M | +275.1% |
| FY2022 | 2022-09-30 | 1.66M | -17.0% |
| FY2021 | 2021-09-30 | 1.99M | — |
Other Income / Expenses vs competitors
How ENTA compares with its peers on the latest reported figures
- ENTA's LTM Mar 2026 other income / expenses of -$1.51M is the 10th highest of the 11 companies compared; the peer median is $5.93M.
- Its year-over-year change of -146.9% is the lowest of 11, against a peer median of -39.6%.
- Other income / expenses amounts to 2.2% of revenue for ENTA, versus a peer median of 29.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.02M | -40.6% | +13.7% | — | |
| LTM Mar 2026 | $10.91M | -38.7% | +40.3% | 29.9% | |
| LTM Mar 2026 | $7.16M | +37.9% | +80.4% | 10.1% | |
| LTM Mar 2026 | $7.03M | -30.0% | +11.2% | — | |
| LTM Mar 2026 | $6.34M | -47.8% | -14.5% | 37.9% | |
| LTM Mar 2026 | $5.52M | -41.1% | +30.8% | 39.8% | |
| LTM Mar 2026 | $5.44M | -67.9% | -1.8% | 19.3% | |
| LTM Mar 2026 | $4.79M | +95.0% | +39.6% | — | |
| LTM Mar 2026 | $2.85M | -27.9% | +11.8% | 1268.0% | |
| LTM Mar 2026 | -$1.51M | -146.9% | +2.8% | 2.2% | |
| LTM Mar 2026 | -$2.06M | -113.1% | — | 18.4% | |
| Peer median (excluding ENTA) | $5.93M | -39.6% | +13.7% | 29.9% | |
Competitors are the stored peer set for ENTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 97.07M | 86.16M | 79.2M | 67.64M | 65.32M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.59M |
| Gross Profit | 97.07M | 86.16M | 79.2M | 67.64M | 60.74M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 93.0% |
| Research & Development | 174.11M | 164.52M | 163.52M | 131.48M | 106.74M |
| Selling, General & Admin | 32.54M | 45.48M | 52.89M | 57.85M | 43.93M |
| Operating Expenses | 206.65M | 210M | 216.41M | 189.33M | 146.09M |
| Depreciation & Amortization | 3.33M | 2.97M | 2.37M | 2.34M | 5.09M |
| EBITDA | (104.25M) | (119.22M) | (123.48M) | (104.51M) | (70.78M) |
| EBITDA Margin | -107.4% | -138.4% | -155.9% | -154.5% | -108.4% |
| Operating Income | (109.57M) | (123.84M) | (137.21M) | (121.69M) | (85.35M) |
| Operating Margin | -112.9% | -143.7% | -173.2% | -179.9% | -130.7% |
| Interest Income | 2.02M | 1.57M | 11.36M | 14.77M | 9.48M |
| Interest Expense | 0 | 0 | 5.15M | 10.94M | 7.68M |
| Other Income / Expenses | 1.99M | 1.66M | 6.21M | 3.9M | 1.8M |
| Income Before Tax | (107.58M) | (122.19M) | (131M) | (117.79M) | (83.55M) |
| Pre-Tax Margin | -110.8% | -141.8% | -165.4% | -174.2% | -127.9% |
| Income Tax Expense | (28.58M) | (433K) | 2.82M | (1.74M) | (1.66M) |
| Net Income | (79M) | (121.76M) | (133.82M) | (116.05M) | (81.89M) |
| Net Margin | -81.4% | -141.3% | -169.0% | -171.6% | -125.4% |
| EPS (Basic) | (3.92) | (5.91) | (6.38) | (5.48) | (3.84) |
| EPS (Diluted) | (3.92) | (5.91) | (6.38) | (5.48) | (3.84) |
| Weighted Avg Shares | 20.17M | 20.6M | 20.97M | 21.16M | 21.34M |
| Weighted Avg Shares (Diluted) | 20.17M | 20.6M | 20.97M | 21.16M | 21.34M |
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
Intrinsic Alpha fair value
Locked
Current Price
$8.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.